Literature DB >> 16005679

Defective rev response element (RRE) and rev gene in HAART treated AIDS patients with discordance between viral load and CD4+ T-cell counts.

Shreesh Saurya1, Zelman Lichtenstein, Abraham Karpas.   

Abstract

BACKGROUND: Highly Active Antiretroviral Therapy (HAART) has emerged as one the most effective method for treating AIDS patients. However, after variable period of treatment, many AIDS patients on HAART show elevated PCR viral load without a corresponding decline in CD4+ T-cells. Our earlier studies have revealed that the viruses present in the plasma of such patients are not infectious.
OBJECTIVE: The aim of this study is to characterize the changes in the regulatory genes of HIV-1, namely tat, rev and rev response element (RRE) isolated from the plasma of such AIDS patients and to assess their role in role in affecting viral infectivity, hence its contribution, in the 'contradictory phenomenon' of high viral load and high CD4+ T-cell counts. STUDY
DESIGN: The viral RNA was isolated from the plasma of HAART patients when they exhibited high plasma viral load and high CD4+ T-cell counts. The target regulatory genes were amplified by RT-PCR and sequenced. Sequences were also obtained from the proviral DNA from the peripheral blood mononuclear cells (PBMCs) of the study subjects. The sequences were compared with the wild type viral sequence to look for the changes induced in them due to HAART regime. RESULTS AND
CONCLUSION: Our data revealed that RRE was missing in the viral particles isolated from the plasma of all study subjects. In two patients, the second exon of the rev gene was missing thereby leading to defective Rev protein. In another patients, Rev synthesis was prematurely stopped due to G135T substitution in the amino terminal domain. No such changes were observed in the corresponding proviral DNA. These changes are likely to result in the assembly of non-infectious virus due to lack of envelope proteins. Absence of RRE and Rev protein also leads to transport and packaging of multiply spliced transcripts into the virions instead of complete genomic RNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005679     DOI: 10.1016/j.jcv.2005.05.003

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  Role of HIV-1 RNA and protein determinants for the selective packaging of spliced and unspliced viral RNA and host U6 and 7SL RNA in virus particles.

Authors:  L Didierlaurent; P J Racine; L Houzet; C Chamontin; B Berkhout; M Mougel
Journal:  Nucleic Acids Res       Date:  2011-07-26       Impact factor: 16.971

Review 2.  HIV infection and HERV expression: a review.

Authors:  Antoinette C van der Kuyl
Journal:  Retrovirology       Date:  2012-01-16       Impact factor: 4.602

3.  Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1.

Authors:  Claudia Arenaccio; Chiara Chiozzini; Sandra Columba-Cabezas; Francesco Manfredi; Maurizio Federico
Journal:  Retrovirology       Date:  2014-06-12       Impact factor: 4.602

4.  The HIV-1 Rev protein enhances encapsidation of unspliced and spliced, RRE-containing lentiviral vector RNA.

Authors:  Bastian Grewe; Katrin Ehrhardt; Bianca Hoffmann; Maik Blissenbach; Sabine Brandt; Klaus Uberla
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

5.  Fully-spliced HIV-1 RNAs are reverse transcribed with similar efficiencies as the genomic RNA in virions and cells, but more efficiently in AZT-treated cells.

Authors:  Laurent Houzet; Zakia Morichaud; Marylène Mougel
Journal:  Retrovirology       Date:  2007-05-02       Impact factor: 4.602

6.  HIV controls the selective packaging of genomic, spliced viral and cellular RNAs into virions through different mechanisms.

Authors:  Laurent Houzet; Jean Christophe Paillart; Fatima Smagulova; Stephan Maurel; Zakia Morichaud; Roland Marquet; Marylène Mougel
Journal:  Nucleic Acids Res       Date:  2007-04-10       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.